Viewing posts for the category Companies

Checkup on My Net Fone (ASX: MNF)

Just as a follow up to this article, here's a quick note on my recent thoughts about My Net Fone.

read more

Is the Medical Developments investment thesis broken? (ASX: MVP)

Well today I sold my shares in Medical Developments International. It was a borderline call, as the thesis is still mostly there. However, the new piece of information was that the company gave the following guidance:

read more

IMF Australia Added to The Hypothetical Ethical Share Portfolio (ASX: IMF)

This is just a short note on IMF Australia (ASX:IMF), [name changing to Bentham IMF] the litigation funders. IMF have recently expanded into the USA, and they had quite low profits in FY 2013. Furthermore, they have just diluted shareholders at a share price of $1.70, and convertible notes are being redeemed at $1.65 per share.

read more

Medical Developments International receives FDA approval for Space Chamber asthma spacers (ASX: MVP)

It has been announced this morning that Medical Developments International has received FDA approval for its Space Chamber asthma spacers. Since I bought shares, the company has moved forward with a number of its initiatives (selling asthma devices into the USA is just one of them). Importantly, the application for marketing approval of Penthrox in Europe has been accepted for consideration. These are both positives. However, the company has also reported reduced sales of Penthrox in Australia, meaning that the shares are no more attractive now than when I bought them, in my opinion. The current price is $1.38 (only slightly above my average entry price).

read more

Vocus Communications is a good long term investment (ASX: VOC)

Introduction to Vocus Communications (ASX: VOC)


Vocus Communications is one of the more attractive companies trading on the ASX, and it’s the company that I have held longest in my portfolio. Earlier this year, the shares were trading under $1.70, at an apparent discount compared to Amcom Telecommunications, which also owns a fibre network and data centres. Surprisingly, even after the company released their preliminary results, I was able to double my holding at about $2.30. At the current price of $3, I still think Vocus offers good value for long-term shareholders, and I have no intention of selling at this price.

read more

Fiducian Portfolio Services announces growing operating cashflow (ASX: FPS)

I bought shares in Fiducian Portfolio Services a couple of weeks ago because, based on a conservative discounted cashflow valuation, I believed their shares were undervalued. I'm now adding Fiducian Portfolio Services to the Hypothetical Sample Ethical Portfolio, with the caveat that 10% of the profits of Fiducian should be donated to charity, because Fiducian is not a particularly ethical investment. The hidden report contains a discussion of the ethics of investing in Fiducian.

read more

Initial coverage of 1300 Smiles Limited (ASX: ONT)

1300 Smiles achieves excellent returns on investment and the Managing Director, Dr Daryl Holmes, appears to have a lot of integrity. He proudly supports charity and owns over 60% of the company, which he founded. The company boasts impressive earnings growth since listing in 2005. The company is providing low cost dental care. The business of the company is to help dentists run more more profitable businesses by allowing them to focus on what they do best: treat patients.

read more

Should I buy Beyond International? (ASX: BYI)

One of my favourite small cap companies, Beyond International (ASX: BYI) has announced a joint venture with Seven Network, owned by Seven West Media (ASX: SWM). Beyond Productions will join forces with Seven to create new programs for the North American market.The JV will be called 7Beyond and is based in Los Angeles.

read more

Should I buy Clover Corporation? (ASX: CLV)

Clover Corporation (ASX: CLV) owns technology that allows them to turn fish oil into a power. Fish oil is a well-known source of Omega-3 which plays a crucial role in brain function. It is normally contained in breast milk and is included in baby formula, and that’s where Clover comes in. 67% of Sales are into Oceania, and that's where the growth is. The company has two divisions. One is responsible for product innovation, the other, Nu-Mega Ingredients, is responsible for commercializing the products. Note: See this edit regarding the ethics of this company.

read more

Why I Bought My Net Fone (ASX: MNF) Again

About 2 months ago I wrote about My Net Fone. By way of history, I had sold my shares at about $1.50 earlier in the year, but the fall in the share price to below $1.20 prompted me to write a short article, in which I concluded (conservatively) that the company would earn about 6c per share. Having thus justified my decision not to buy shares at $1.20, I carefully avoided considering whether affirmation bias might have swayed me (after all, I had decided the shares were over valued at just $1.50). Further evidence that I have a way to go developing my investing temperament.

read more